The German laboratory BioNTech announced that it was urgently studying the efficacy of the COVID-19 vaccine it developed with Pfizer to see if it protects against the new B.1.1.529 variant detected in South Africa.
“We expect more data from laboratory tests in two weeks maximum”Said a spokesperson.
“These data will provide more information on whether B.1.1.529 could be a variant that might require adjustment of our vaccine if the variant spreads globally.”He added.
The detection of this new variant by South African scientists has triggered global alarm, with concerns that its numerous mutations could make it even more dangerous than the highly contagious Delta variant.
Following the announcement, several countries – including the United Kingdom, Italy and Germany – decided to close their doors to travelers from various southern African states.
According to BioNTech, variant B.1.1.529 “clearly differs from known variants because it has additional mutations in the spike protein”.
“Pfizer and BioNTech prepared several months ago to adjust their vaccine in less than six weeks and deliver the first doses in 100 days.“If a variant was resistant, stressed the laboratory spokesperson.
.
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
